Search - tctmd.com

Displaying 1 - 16 of 16

Sort: Relevancy | Date

News Daily News

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Michael O'Riordan

April 17, 2024

News Features

Skyrocketing Popularity Puts GLP-1 Agonists for Weight Loss on Cardiology’s Radar

L.A. McKeown

May 12, 2023

News Conference News ACC 2023

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Michael O'Riordan

March 04, 2023

News Daily News

Semaglutide Effective for Weight Loss in Adolescents: STEP TEENS

Michael O'Riordan

December 30, 2022

News Daily News

British Medical Groups Express Concern About Inclisiran Rollout

Michael O'Riordan

December 14, 2021

News Daily News

FDA Passes on Inclisiran, Citing Manufacturing Site Problems

Shelley Wood

December 23, 2020

News Daily News

Women, Elderly, Minorities Vastly Underrepresented in Clinical Trials Over Decades

Yael L. Maxwell

May 28, 2020

News Daily News

FDA Approves New Lipid-Lowering Drug, Bempedoic Acid

Shelley Wood

February 26, 2020

News Daily News

FDA Approves Icosapent Ethyl for Reducing CVD Events

Michael O'Riordan

December 13, 2019

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

News Daily News

New AHA Guidance on Omega-3 Fatty Acids for High Triglycerides

Michael O'Riordan

August 21, 2019

News Features

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

Shelley Wood

October 22, 2018

News Daily News

It’s Official: Evolocumab Gains Claim for CVD Event Reduction

Michael O'Riordan

December 04, 2017

News Daily News

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

Michael O'Riordan

October 19, 2017

News Daily News

FDA: No Cardiovascular Event Reduction Claim for Ezetimibe

Shelley Wood

February 16, 2016

News Daily News

NHLBI Stops High-Dose Niacin Trial Early Due to Lack of Efficacy

May 27, 2011

Advertisement

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Skyrocketing Popularity Puts GLP-1 Agonists for Weight Loss on Cardiology’s Radar

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Semaglutide Effective for Weight Loss in Adolescents: STEP TEENS

British Medical Groups Express Concern About Inclisiran Rollout

FDA Passes on Inclisiran, Citing Manufacturing Site Problems

Women, Elderly, Minorities Vastly Underrepresented in Clinical Trials Over Decades

FDA Approves New Lipid-Lowering Drug, Bempedoic Acid

FDA Approves Icosapent Ethyl for Reducing CVD Events

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

New AHA Guidance on Omega-3 Fatty Acids for High Triglycerides

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

It’s Official: Evolocumab Gains Claim for CVD Event Reduction

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

FDA: No Cardiovascular Event Reduction Claim for Ezetimibe

NHLBI Stops High-Dose Niacin Trial Early Due to Lack of Efficacy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content